Publicaciones en las que colabora con Maria Angeles Muñoz Fernandez (32)

2022

  1. Impact of Gestational COVID-19 on Neonatal Outcomes: Is Vertical Infection Possible?

    The Pediatric infectious disease journal, Vol. 41, Núm. 6, pp. 466-472

2012

  1. Detectable viral load aggravates immunosenescence features of CD8 T-cell subsets in vertically HIV-infected children

    Journal of Acquired Immune Deficiency Syndromes, Vol. 60, Núm. 5, pp. 447-454

2011

  1. Cardiovascular risk markers are increased in HIV-infected children with lipodystrophy syndrome

    Journal of Infection

2009

  1. Correlation between the Trofile® test and virological response to a short-term maraviroc exposure in HIV-infected patients

    Journal of Antimicrobial Chemotherapy, Vol. 64, Núm. 4, pp. 845-849

2008

  1. Immunological recovery and metabolic disorders in severe immunodeficiency HIV type 1-infected children on highly active antiretroviral therapy

    AIDS Research and Human Retroviruses, Vol. 24, Núm. 12, pp. 1477-1484

  2. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 1, pp. 183-190

2007

  1. Carga viral plasmática en niños infectados por el virus de la inmunodeficiencia humana que reciben tratamiento antirretroviral de gran actividad

    Medicina Clinica, Vol. 128, Núm. 2, pp. 49-51

  2. Effect of a bone marrow microenvironment on the ex-vivo expansion of umbilical cord blood progenitor cells

    International Journal of Laboratory Hematology, Vol. 29, Núm. 1, pp. 58-63

  3. Prevalencia de resistencia a fármacos antirretrovirales en España

    Anales de Pediatria, Vol. 67, Núm. 2, pp. 104-108

2006

  1. CD4+ T-cell immunodeficiency is more dependent on immune activation than viral load in HIV-infected children on highly active antiretroviral therapy

    Journal of Acquired Immune Deficiency Syndromes, Vol. 42, Núm. 3, pp. 269-276

  2. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children

    BMC Infectious Diseases, Vol. 6

  3. Impact of long-term viral suppression in CD4+ recovery of HIV-children on Highly Active Antiretroviral Therapy

    BMC Infectious Diseases, Vol. 6

  4. Interleukin-7 levels before highly active antiretroviral therapy may predict CD4+ T-cell recovery and virological failure in HIV-infected children [5]

    Journal of Antimicrobial Chemotherapy

  5. La terapia combinada puede ser tan efectiva como la terapia antirretroviral de alta eficacia en el control de la carga viral en niños con un sistema inmunitario conservado

    Acta Pediatrica Espanola, Vol. 64, Núm. 8, pp. 377-382

  6. Low immunologic response to highly active antiretroviral therapy in naive vertically human immunodeficiency virus type 1-infected children with severe immunodeficiency

    Pediatric Infectious Disease Journal, Vol. 25, Núm. 4, pp. 365-368

2004

  1. HIV-infected children with moderate/severe immune-suppression: Changes in the immune system after highly active antiretroviral therapy

    Clinical and Experimental Immunology, Vol. 137, Núm. 3, pp. 570-577

  2. The effects on infants of potent antiretroviral therapy during pregnancy: A report from Spain

    Medical Science Monitor, Vol. 10, Núm. 5

  3. Tratamiento «in utero» con células madre hematopoyéticas: ¿Para qué?

    Acta Pediatrica Espanola, Vol. 62, Núm. 5, pp. 206-210

2003

  1. CD8+ T-cell numbers predict the response to antiviral therapy in HIV-1-infected children

    Pediatric Research, Vol. 53, Núm. 2, pp. 309-312

  2. Characterizing the immune system after long-term undetectable viral load in HIV-1-infected children

    Journal of Clinical Immunology, Vol. 23, Núm. 4, pp. 279-289